Katharina Koepsel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Katharina Koepsel has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Mügge
Department of Cardiology and Rhythmology, St. Josef Hospital, Ruhr University Bochum , Bochum
2 shared publications - Hendrik Lapp
Heart Centre Bonn, Department of Medicine II, University Hospital Bonn , Venusberg-Campus 1, Bonn D-53127
2 shared publications - Ibrahim Akin
Section of Invasive Cardiology and Electrophysiology, Department of Internal medicine I, University Medical Center Mannheim, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany
2 shared publications - Ibrahim El-Battrawy
Institute of Physiology, Department of Cellular and Translational Physiology, Medical Faculty, Ruhr University of Bochum, 44801 Bochum, Germany
2 shared publications - Mohammad Abumayyaleh
Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany
2 shared publications - Nazha Hamdani
Ruhr-University Bochum, Medical Faculty, Institute of Physiology, Department of Cellular and Translational Physiology, Bochum, Germany
2 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (11)
Early ventricular tachyarrhythmia after myocardial infarction in patients using a wearable cardioverter defibrillator
- 31 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (11)
Open AccessEarly ventricular tachyarrhythmia after myocardial infarction in patients using a wearable cardioverter defibrillator
- Open Access
- 19 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (18) , e030615
Use of the Wearable Cardioverter‐Defibrillator Among Patients With Myocarditis and Reduced Ejection Fraction or Ventricular Tachyarrhythmia: Data From a Multicenter Registry
Background: Data on the use of the wearable cardioverter‐defibrillator (WCD) among patients with myocarditis remain sparse. Consequently, evidence for guideline recommendations in this patient population is lacking. Methods and Results: In total, 1596 consecutive patients were included in a multicenter registry from 8 European centers, with 124 patients (8%) having received the WCD due to myocarditis and reduced left ventricular ejection fraction or prior ventricular tachyarrhythmia. The mean age was 51.6±16.3 years, with 74% being male. Patients were discharged after index hospitalization on heart failure medication: Angiotensin‐converting enzyme inhibitors (62.5%), angiotensin‐receptor‐neprilysin inhibitor (22.9%), aldosterone‐antagonists (51%), or beta blockers (91.4%). The initial median left ventricular ejection fraction was 30% (22%–45%) and increased to 48% (39%–55%) over long‐term follow‐up ( P P =0.022). The mean wear time was 79.7±52.1 days and 21.0±4.9 hours per day. Arrhythmic event rates documented by the WCD were 9.7% for nonsustained ventricular tachycardia, 6.5% for sustained ventricular tachycardia, and 0% for ventricular fibrillation. Subsequently, 2.4% of patients experienced an appropriate WCD shock. The rate of inappropriate WCD shocks was 0.8%. All 3 patients with appropriate WCD shock had experienced ventricular tachycardia/ventricular fibrillation before WCD prescription, with only 1 patient showing a left ventricular ejection fraction <35%. Conclusions: Patients with myocarditis and risk for occurrence of ventricular tachyarrhythmia may benefit from WCD use. Prior ventricular arrhythmia might appear as a better risk predictor than a reduced left ventricular ejection fraction <35% in this population.
- 19 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (18) , e030615
Open AccessUse of the Wearable Cardioverter‐Defibrillator Among Patients With Myocarditis and Reduced Ejection Fraction or Ventricular Tachyarrhythmia: Data From a Multicenter Registry
Background: Data on the use of the wearable cardioverter‐defibrillator (WCD) among patients with myocarditis remain sparse. Consequently, evidence for guideline recommendations in this patient population is lacking. Methods and Results: In total, 1596 consecutive patients were included in a multicenter registry from 8 European centers, with 124 patients (8%) having received the WCD due to myocarditis and reduced left ventricular ejection fraction or prior ventricular tachyarrhythmia. The mean age was 51.6±16.3 years, with 74% being male. Patients were discharged after index hospitalization on heart failure medication: Angiotensin‐converting enzyme inhibitors (62.5%), angiotensin‐receptor‐neprilysin inhibitor (22.9%), aldosterone‐antagonists (51%), or beta blockers (91.4%). The initial median left ventricular ejection fraction was 30% (22%–45%) and increased to 48% (39%–55%) over long‐term follow‐up ( P P =0.022). The mean wear time was 79.7±52.1 days and 21.0±4.9 hours per day. Arrhythmic event rates documented by the WCD were 9.7% for nonsustained ventricular tachycardia, 6.5% for sustained ventricular tachycardia, and 0% for ventricular fibrillation. Subsequently, 2.4% of patients experienced an appropriate WCD shock. The rate of inappropriate WCD shocks was 0.8%. All 3 patients with appropriate WCD shock had experienced ventricular tachycardia/ventricular fibrillation before WCD prescription, with only 1 patient showing a left ventricular ejection fraction <35%. Conclusions: Patients with myocarditis and risk for occurrence of ventricular tachyarrhythmia may benefit from WCD use. Prior ventricular arrhythmia might appear as a better risk predictor than a reduced left ventricular ejection fraction <35% in this population.